Evidence map›Paper›PMID 25512415›Full record

ArticleAntimicrobial agents and chemotherapy2015

Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar.

Lili Yuan, Ying Wang, Daniel M Parker, Bhavna Gupta, Zhaoqing Yang, Huaie Liu, Qi Fan, Yaming Cao, Yuping Xiao, Ming-chieh Lee and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 4 syntheses or guidelines pooled it, 69 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Efficacy of Primaquine for the Radical Cure of Plasmodium vivax Malaria in Northeast Myanmar and the Impact of Cytochrome P450 2D6 Genotypes.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025
    Article
  9. Article
  10. Article
  11. Observational
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Prevalence ofMicroorganisms · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 4 countries.

Lili YuanDepartment of Pathogen Biology and Immunology, Kunming Medical University, Kunming, China Department of Entomology, Pennsylvania State University, University Park, Pennsylvania, USA.
Ying WangInstitute of Tropical Medicine, Third Military Medical University, Chongqing, China.
Daniel M ParkerDepartment of Entomology, Pennsylvania State University, University Park, Pennsylvania, USA.
Bhavna GuptaDepartment of Entomology, Pennsylvania State University, University Park, Pennsylvania, USA.
Zhaoqing YangDepartment of Pathogen Biology and Immunology, Kunming Medical University, Kunming, China.
Huaie LiuDepartment of Pathogen Biology and Immunology, Kunming Medical University, Kunming, China.
Qi FanDalian Institute of Biotechnology, Dalian, Liaoning, China.
Yaming CaoDepartment of Immunology, China Medical University, Shenyang, China.
Yuping XiaoDepartment of Immunology, China Medical University, Shenyang, China.
Ming-chieh LeeProgram in Public Health, University of California at Irvine, Irvine, California, USA.
Guofa ZhouProgram in Public Health, University of California at Irvine, Irvine, California, USA.
Guiyun YanProgram in Public Health, University of California at Irvine, Irvine, California, USA.
J Kevin BairdEijkman-Oxford Clinical Research Unit, Jakarta, Indonesia Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
Liwang CuiDepartment of Entomology, Pennsylvania State University, University Park, Pennsylvania, USA luc2@psu.edu.
Pennsylvania State University · USUniversity of California, Irvine · USChina Medical University · CNKunming Medical University · CNArmy Medical University · CNOxford University Clinical Research Unit Indonesia

Funding

Southeast Asia Malaria Research CenterU19AI089672 · NIAID · UNIVERSITY OF SOUTH FLORIDA · PI CUI, LIWANG · 2010 to 2023
$28.9M
NIAID NIH HHS U19 AI089672NIAID NIH HHS U19AI089672Wellcome Trust 089276Wellcome Trust B9RJIXO
6 · The paper itself

Abstract

Chloroquine-primaquine (CQ-PQ) continues to be the frontline therapy for radical cure of Plasmodium vivax malaria. Emergence of CQ-resistant (CQR) P. vivax parasites requires a shift to artemisinin combination therapies (ACTs), which imposes a significant financial, logistical, and safety burden. Monitoring the therapeutic efficacy of CQ is thus important. Here, we evaluated the therapeutic efficacy of CQ-PQ for P. vivax malaria in northeast Myanmar. We recruited 587 patients with P. vivax monoinfection attending local malaria clinics during 2012 to 2013. These patients received three daily doses of CQ at a total dose of 24 mg of base/kg of body weight and an 8-day PQ treatment (0.375 mg/kg/day) commencing at the same time as the first CQ dose. Of the 401 patients who finished the 28-day follow-up, the cumulative incidence of recurrent parasitemia was 5.20% (95% confidence interval [CI], 3.04% to 7.36%). Among 361 (61%) patients finishing a 42-day follow-up, the cumulative incidence of recurrent blood-stage infection reached 7.98% (95% CI, 5.20% to 10.76%). The cumulative risk of gametocyte carriage at days 28 and 42 was 2.21% (95% CI, 0.78% to 3.64%) and 3.93% (95% CI, 1.94% to 5.92%), respectively. Interestingly, for all 15 patients with recurrent gametocytemia, this was associated with concurrent asexual stages. Genotyping of recurrent parasites at the merozoite surface protein 3α gene locus from 12 patients with recurrent parasitemia within 28 days revealed that 10 of these were the same genotype as at day 0, suggesting recrudescence or relapse. Similar studies in 70 patients in the same area in 2007 showed no recurrent parasitemias within 28 days. The sensitivity to chloroquine of P. vivax in northeastern Myanmar may be deteriorating.

Indexed as

AdolescentAdultAgedAntimalarialsChildChild, PreschoolChloroquineFemaleGenotypeHumansInfantMalaria, VivaxMaleMiddle AgedPlasmodium vivaxPrimaquineAntimalarialsChloroquinePrimaquine

Identifiers

PMID25512415
PMCPMC4335844
OpenAlexW2096507245

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.